FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2099667080> ?p ?o ?g. }

• W2099667080 abstract "Abstract Background The NeoAzure study has demonstrated that the use of the bisphosphonate zoledronic acid (Zol) in the neoadjuvant setting increases the rate of complete response in primary breast cancer and therefore indicates direct antitumor activity. The purpose of this study was to compare the antitumor effect of Zol with standard chemotherapy in primary breast cancer cells using ATP-tumor chemosensitivity assay (ATP-TCA). Methods Breast cancer specimens were obtained from patients with breast cancer who underwent primary breast cancer surgery at the Department of Obstetrics and Gynecology, Tübingen, Germany, between 2006 through 2009. Antitumor effects of Zol, TAC (Docetaxel, Adriamycin, Cyclophosphamide) and FEC (5-Fluorouracil, Epirubicin, Cyclophosphamide) were tested in 116 fresh human primary breast cancer specimens using ATP-TCA. ATP-TCA results were analyzed with different cut-off levels for the half maximal inhibitory concentration (IC50), for IC90 and for the sensitivity index (IndexSUM). Each single agent or combination was tested at six doubling dilutions from 6.25, 12.5, 25, 50, 100, and 200% of test drug concentrations (TDC) derived from the plasma peak concentrations determined by pharmacokinetic data. The assay was carried out in duplicate wells with positive and negative controls. Results The median IndexSUM value was lower for Zol than for the combined regimen FEC (36.8%) and TAC (12.9%), respectively, indicating increased antitumor activity of Zol in primary breast cancer cells. The difference regarding Zol and FEC was significant (p < 0.05). The median IC50 value for Zol (8.03% TDC) was significantly lower than the IC50 values for FEC (33.5% TDC) and TAC (19.3% TDC) treatment (p < 0.05). However, the median IC90 value for Zol (152.5% TDC) was significantly higher than the IC90 value obtained with TAC (49.5% TDC; p < 0.05), but similar to the IC90 value for FEC (180.9% TDC). In addition a significant positive correlation was observed for the IndexSum of Zol and the ER status (p < 0.01). Conclusion Zoledronic acid has a strong antitumor effect on primary breast cancer cells in vitro which is equal or superior to commonly used chemotherapeutic regimens for treating breast cancer." @default.
• W2099667080 created "2016-06-24" @default.
• W2099667080 creator A5011069826 @default.
• W2099667080 creator A5032246802 @default.
• W2099667080 creator A5040233864 @default.
• W2099667080 creator A5054303873 @default.
• W2099667080 creator A5086791040 @default.
• W2099667080 date "2012-07-23" @default.
• W2099667080 modified "2023-09-25" @default.
• W2099667080 title "Antitumor activity of zoledronic acid in primary breast cancer cells determined by the ATP tumor chemosensitivity assay" @default.
• W2099667080 cites W1862785984 @default.
• W2099667080 cites W1917534569 @default.
• W2099667080 cites W1967875617 @default.
• W2099667080 cites W1976920463 @default.
• W2099667080 cites W1977203209 @default.
• W2099667080 cites W1989014251 @default.
• W2099667080 cites W1990455553 @default.
• W2099667080 cites W2000293927 @default.
• W2099667080 cites W2021852492 @default.
• W2099667080 cites W2029353393 @default.
• W2099667080 cites W2031141963 @default.
• W2099667080 cites W2039701074 @default.
• W2099667080 cites W2041868422 @default.
• W2099667080 cites W2060736857 @default.
• W2099667080 cites W2067172842 @default.
• W2099667080 cites W2076769374 @default.
• W2099667080 cites W2077073060 @default.
• W2099667080 cites W2096360340 @default.
• W2099667080 cites W2104518011 @default.
• W2099667080 cites W2107118598 @default.
• W2099667080 cites W2122911205 @default.
• W2099667080 cites W2132747627 @default.
• W2099667080 cites W2137539267 @default.
• W2099667080 cites W2143939516 @default.
• W2099667080 cites W2148096512 @default.
• W2099667080 cites W2148226416 @default.
• W2099667080 cites W2151802968 @default.
• W2099667080 cites W2152409486 @default.
• W2099667080 cites W2155937162 @default.
• W2099667080 cites W2156683343 @default.
• W2099667080 cites W2159436449 @default.
• W2099667080 doi "https://doi.org/10.1186/1471-2407-12-308" @default.
• W2099667080 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3416722" @default.
• W2099667080 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22824103" @default.
• W2099667080 hasPublicationYear "2012" @default.
• W2099667080 type Work @default.
• W2099667080 sameAs 2099667080 @default.
• W2099667080 citedByCount "15" @default.
• W2099667080 countsByYear W20996670802013 @default.
• W2099667080 countsByYear W20996670802014 @default.
• W2099667080 countsByYear W20996670802015 @default.
• W2099667080 countsByYear W20996670802016 @default.
• W2099667080 countsByYear W20996670802017 @default.
• W2099667080 countsByYear W20996670802018 @default.
• W2099667080 countsByYear W20996670802019 @default.
• W2099667080 countsByYear W20996670802022 @default.
• W2099667080 crossrefType "journal-article" @default.
• W2099667080 hasAuthorship W2099667080A5011069826 @default.
• W2099667080 hasAuthorship W2099667080A5032246802 @default.
• W2099667080 hasAuthorship W2099667080A5040233864 @default.
• W2099667080 hasAuthorship W2099667080A5054303873 @default.
• W2099667080 hasAuthorship W2099667080A5086791040 @default.
• W2099667080 hasBestOaLocation W20996670801 @default.
• W2099667080 hasConcept C121608353 @default.
• W2099667080 hasConcept C126322002 @default.
• W2099667080 hasConcept C126894567 @default.
• W2099667080 hasConcept C143998085 @default.
• W2099667080 hasConcept C2776326535 @default.
• W2099667080 hasConcept C2776694085 @default.
• W2099667080 hasConcept C2776755627 @default.
• W2099667080 hasConcept C2778076430 @default.
• W2099667080 hasConcept C2780140570 @default.
• W2099667080 hasConcept C2780835546 @default.
• W2099667080 hasConcept C2781190966 @default.
• W2099667080 hasConcept C530470458 @default.
• W2099667080 hasConcept C71924100 @default.
• W2099667080 hasConcept C98274493 @default.
• W2099667080 hasConceptScore W2099667080C121608353 @default.
• W2099667080 hasConceptScore W2099667080C126322002 @default.
• W2099667080 hasConceptScore W2099667080C126894567 @default.
• W2099667080 hasConceptScore W2099667080C143998085 @default.
• W2099667080 hasConceptScore W2099667080C2776326535 @default.
• W2099667080 hasConceptScore W2099667080C2776694085 @default.
• W2099667080 hasConceptScore W2099667080C2776755627 @default.
• W2099667080 hasConceptScore W2099667080C2778076430 @default.
• W2099667080 hasConceptScore W2099667080C2780140570 @default.
• W2099667080 hasConceptScore W2099667080C2780835546 @default.
• W2099667080 hasConceptScore W2099667080C2781190966 @default.
• W2099667080 hasConceptScore W2099667080C530470458 @default.
• W2099667080 hasConceptScore W2099667080C71924100 @default.
• W2099667080 hasConceptScore W2099667080C98274493 @default.
• W2099667080 hasIssue "1" @default.
• W2099667080 hasLocation W20996670801 @default.
• W2099667080 hasLocation W20996670802 @default.
• W2099667080 hasLocation W20996670803 @default.
• W2099667080 hasLocation W20996670804 @default.
• W2099667080 hasOpenAccess W2099667080 @default.
• W2099667080 hasPrimaryLocation W20996670801 @default.
• W2099667080 hasRelatedWork W2066533124 @default.
• W2099667080 hasRelatedWork W2220745506 @default.

• next